Peer-reviewed veterinary case report
How to safely dose radioiodine for cats with hyperthyroidism
By Peterson, Mark E & Rishniw, Mark·Published in Journal of veterinary internal medicine·2021·Animal Endocrine Clinic, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A dosing algorithm for individualized radioiodine treatment of cats with hyperthyroidism.
- Species:
- cat
Plain-English summary
A group of hyperthyroid cats were treated with a new method for calculating the right dose of radioiodine, which is the best treatment for this condition. The goal was to effectively manage their hyperthyroidism while reducing the risk of causing low thyroid hormone levels or kidney problems. After treatment, about 75% of the cats returned to normal thyroid function, while a small number developed low thyroid levels or remained hyperthyroid. This new dosing approach seems to be safer and just as effective as older methods.
People also search for: cat hyperthyroidism treatment · radioiodine dose for cats · symptoms of low thyroid in cats
Abstract
BACKGROUND: Radioiodine (I) is the treatment of choice for hyperthyroidism in cats, but currentI-dosing protocols can induce iatrogenic hypothyroidism and expose azotemia. OBJECTIVES: To develop a cat-specific algorithm to calculate the lowestI dose to resolve hyperthyroidism, while minimizing risk of iatrogenic hypothyroidism and subsequent azotemia. ANIMALS: One thousand and four hundred hyperthyroid cats treated withI. METHODS: Prospective case series (before-and-after study). All cats had serum concentrations of thyroxine (T), triiodothyronine (T), and thyroid-stimulating hormone (TSH) measured (off methimazole ≥1 week). Using thyroid scintigraphy, each cat's thyroid volume and percent uptake ofTc-pertechnatate (TcTU) were determined. An initialI dose was calculated by averaging dose scores for T/Tconcentrations, thyroid volume, and TcTU; 80% of that composite dose was administered. Twenty-four hours later, percentI uptake was measured, and additionalI administered, as needed, to deliver an adequate radiation dose to the thyroid tumor(s). Serum concentrations of T, TSH, and creatinine were determined 6 to 12 months later. RESULTS: The median calculatedI dose was 1.9 mCi (range, 1.0-10.6 mCi); 1380 cats required additionalI administration on day 2. Of the cats, 1047 (74.8%) became euthyroid, 57 (4.1%) became overtly hypothyroid, 240 (17.1%) became subclinically hypothyroid, and 56 (4%) remained hyperthyroid. More overtly (71.9%) and subclinically (39.6%) hypothyroid cats developed azotemia than euthyroid cats (14.2%; P < .0001). CONCLUSIONS AND CLINICAL IMPORTANCE: Our algorithm for calculating individualI doses resulted in cure rates similar to historical treatment rates, despite much lowerI doses. This algorithm appears to lower prevalence of bothI-induced overt hypothyroidism and azotemia.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34351027/